Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06757764 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Study acronym: CHANGE
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria revisedv6
  2. Site details revised at 19 of 24 sitesv5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 24
    • Start date changed from estimate of Jun 30, 2025 to Jul 10, 2025
    v4
  4. Start date: Mar 15, 2025 to Jun 30, 2025v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Asan Medical Center
92 trials monitored
See 1 trial at risk
Stroke
3,531 trials monitored
See 153 trials at risk
Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.
Trial Details
NCT Number NCT06757764
Lead Sponsor Asan Medical Center
Collaborators: Korea Otsuka Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Cerebral Infarction, Stenosis Artery
Related terms Cerebral Infarction
Enrollment 2,340 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov